Ignite Creation Date:
2025-12-25 @ 1:41 AM
Ignite Modification Date:
2026-02-25 @ 8:31 PM
Study NCT ID:
NCT02822794
Status:
COMPLETED
Last Update Posted:
2018-11-14
First Post:
2016-06-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-07-25
Start Date Type:
ACTUAL
Primary Completion Date:
2017-06-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08-25
Completion Date Type:
ACTUAL
First Submit Date:
2016-06-30
First Submit QC Date:
None
Study First Post Date:
2016-07-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-05-24
Results First Submit QC Date:
None
Results First Post Date:
2018-07-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-10-19
Last Update Post Date:
2018-11-14
Last Update Post Date Type:
ACTUAL